Peter St. Phillip is a partner in the firm and co-head of the firm's antitrust department. He regularly represents institutional clients in large-scale cost recovery litigation. His primary clients include large health insurers, such as CIGNA and Horizon, and hedge funds and other investment companies.
Mr. St. Phillip has extensive appellate experience, stemming from his clerkship with the United States Court of Appeals for the Third Circuit. He has lectured on appellate advocacy and routinely briefs and argues appeals in the federal circuit courts.
Mr. St. Phillip successfully argued Aetna’s appeal before the United States Court of Appeals for the First Circuit in In re Neurontin Mktg. & Sales Practices Litigation, 712 F.3d 51 (1st Cir. 2013), a landmark RICO decision holding drug manufacturers accountable to health insurers for damages attributable to marketing fraud. He appeared prominently in the April 4, 2013 National Law Journal along with his quote concerning the decision, “Pfizer Suffers Big Setback in Trio of Appellate Rulings,” National Law Journal (Apr. 4, 2013).
Through his appellate practice, Mr. St. Phillip has also been instrumental in securing decisions invalidating agency regulations, Roussos v. Menifee, 122 F.3d 159 (3d Cir. 1997), upholding summary judgment, In re Cardizem CD Antitrust Litig., 332 F.3d 896 (6th Cir. 2003), affirming settlements, In re Cardizem CD Antitrust Litig., 391 F.3d 812 (6th Cir. 2004) and reversing dismissals, In re: Avandia Mktg., Sales Prac. & Prods. Liab. Litig., 685 F.3d 353 (3d Cir. 2012), cert. denied, 12-690, 2013 WL 1500235 (U.S. Apr. 15, 2013); Desiano v. Warner-Lambert Co., 326 F.3d 339 (2d Cir. 2003).
Mr. St. Phillip has prosecuted a large number of antitrust and cost recovery matters during his career, including trying cases to verdict. He has developed and defended expert economic testimony in connection with successful prosecutions of commodity manipulation securities claims, prescription drug cases and antitrust matters. He is responsible for day-to-day litigation efforts in several antitrust and pharmaceutical and healthcare engagements. Mr. St. Phillip has extensive expertise in complex litigation concerning medical and pharmaceutical cost recovery claims and pharmacy benefits management. Mr. St. Phillip is a contributing editor to the American Bar Association's Antitrust Class Actions Handbook, and often publishes and speaks on antitrust issues.
Mr. St. Phillip has taken an active role in litigating antitrust issues relative to collusive interbank rate-setting conduct in the financial industry. He served as a panelist discussing these issues during the 2014 New York City Bar Association Financial Services forum and has been published on the topic: Competition Policy Cartel International’s Cartel Column “No Antitrust Injury in Rate-Setting—What Happened to Effects?” (May 30, 2013).
Mr. St. Phillip has represented hedge funds in insurance coverage and securities litigation. He also regularly represents a publicly-traded bank in defense of claims involving state and federal lending disclosure and trade practices laws. Mr. St. Phillip graduated with honors from Seton Hall University School of Law (J.D., cum laude, 1993) and received a Bachelor of Arts from Trinity College (1990). He is admitted to practice in New York, New Jersey and Pennsylvania, and is a member of the bars of the U.S. Courts of Appeals for the 1st, 2nd, 3rd, 5th, 6th, 8th and 9th Circuits; and the U.S. District Courts for the Southern and Eastern Districts of New York, the District of New Jersey, the Eastern District of Pennsylvania and the District of Connecticut.